FDA warns Dr. Ehsan Sadri that two ineligible subjects received an investigational drug in clinical trials.
What happened
FDA inspected Dr. Sadri's clinical site from March 27 to April 16, 2025. FDA found that he enrolled and gave study drug to two subjects who did not meet protocol eligibility criteria: one lacked a required screening cell-density measurement, and one had eye pressure outside the required range. Two of nine randomized and treated subjects at the site were ineligible.
What FDA found
The investigator enrolled a subject who did not have the required central corneal endothelial cell density measurement at screening.
21 CFR 312.60The investigator enrolled a subject whose eye pressure at randomization was 16 mmHg in each eye, outside the protocol-required eligibility range.
21 CFR 312.60Two of nine randomized and treated subjects at the site were ineligible for enrollment.
21 CFR 312.60
What FDA wants
FDA tells Dr. Sadri to write within 15 business days describing actions taken to prevent similar violations and to provide enough detail on oversight and procedure changes. It says failure to address the matter adequately may lead to regulatory action without further notice.
Who should pay attention
- clinical research sites and principal investigators
- sponsors and CROs relying on site eligibility data
- IRBs and study monitors overseeing enrollment
This is a summary. Read the original letter on fda.gov.